Search

Your search keyword '"Westervelt, Peter"' showing total 1,294 results

Search Constraints

Start Over You searched for: Author "Westervelt, Peter" Remove constraint Author: "Westervelt, Peter"
1,294 results on '"Westervelt, Peter"'

Search Results

1. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

3. Genomic landscape of TP53-mutated myeloid malignancies

4. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study

5. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

6. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes

7. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

8. Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study

9. Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma

11. Proteomic and phosphoproteomic landscapes of acute myeloid leukemia

12. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial

14. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)

15. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102

17. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

19. Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor

23. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

26. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

27. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

28. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

29. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

30. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

31. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

32. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

33. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

34. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

35. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

36. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

37. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

38. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia

39. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma

42. Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes

43. Supplementary Table from Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

44. Supplementary Table from Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia

45. Supplementary Figure from Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

46. Data from Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

47. Supplementary Data from Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

48. Supplementary Data from Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia

49. Data from Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia

50. Data from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Catalog

Books, media, physical & digital resources